A unifying approach for surrogate marker validation based on Prentice's criteria

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Statistics in Medicine

• Publication date

  2006-01-30

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1002/sim.2315PMID 16220497
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Surrogate endpoints: A basis for a rational approach

  2006cited by this paper
• Choice of units of analysis and modeling strategies in multilevel hierarchical models

  2004cited by this paper
• Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach

  2004cited by this paper
• Validation of a longitudinally measured surrogate marker for a time-to-event endpoint

  2003cited by this paper
• Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements

  2003influential reference
• Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes

  2002cited by this paper
• INVESTIGATING THE CRITERION VALIDITY OF PSYCHIATRIC SYMPTOM SCALES USING SURROGATE MARKER VALIDATION METHODOLOGY

  2002cited by this paper
• Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes

  2001cited by this paper
• Joint modelling of longitudinal measurements and event time data.

  2000cited by this paper
• The validation of surrogate endpoints in meta-analyses of randomized experiments.

  2000cited by this paper
• The Analysis of Designed Experiments and Longitudinal Data by Using Smoothing Splines

  1999cited by this paper
• The analysis of designed experiments and longitudinal data by using smoothing splines - Discussion

  1999cited by this paper
• Criteria for the validation of surrogate endpoints in randomized experiments.

  1998cited by this paper
• Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Pharmacological Therapy for Macular Degeneration Study Group.

  1997cited by this paper
• Meta-analysis for the evaluation of potential surrogate markers.

  1997cited by this paper
• Estimating the proportion of treatment effect explained by a surrogate marker.

  1997cited by this paper
• Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration

  1997cited by this paper
• Surrogate End Points in Clinical Trials: Are We Being Misled?

  1996cited by this paper
• General class of covariance structures for two or more repeated factors in longitudinal data analysis

  1994influential reference
• Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research.

  1994cited by this paper
• Statistical validation of intermediate endpoints for chronic diseases.

  1992cited by this paper
• Surrogate endpoints in clinical trials: definition and operational criteria.

  1989cited by this paper
• Information gain and a general measure of correlation

  1983cited by this paper

• Individual-level surrogacy of MRI lesions for disease severity in RRMS: Methods to quantify predictive power and their application to longitudinal data from recent trials

  2025cites this paper
• The Experimental Selection Correction Estimator: Using Experiments to Remove Biases in Observational Estimates

  2025cites this paper
• A Causal Perspective on Label Bias

  2024cites this paper
• Assessment of digital perfusion as a surrogate outcome in Raynaud's phenomenon clinical trials.

  2023cites this paper
• Informed decision‐making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments

  2022cites this paper
• Separation and the information theory surrogate evaluation approach: A penalised likelihood solution

  2021cites this paper
• Is Disease Intensity a Good Surrogate for Yield Loss or Toxin Contamination? A Case Study with Fusarium Head Blight of Wheat.

  2020cites this paper
• Combining Experimental and Observational Data to Estimate Treatment Effects on Long Term Outcomes

  2020cites this paper
• Using Experiments to Correct for Selection in Observational Studies

  2020cites this paper
• The Surrogate Index: Combining Short-Term Proxies to Estimate Long-Term Treatment Effects More Rapidly and Precisely

  2019influential citation
• Biomarkers of Kidney Injury and Rejection

  2019cites this paper
• Measuring Surrogacy in Clinical Research

  2019cites this paper
• One‐step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure‐time endpoints

  2019cites this paper
• Evaluation of surrogacy in the multi-trial setting based on information theory: an extension to ordinal outcomes

  2019influential citation
• Statistical Considerations for Quantitative Imaging Measures in Clinical Trials

  2018cites this paper
• The Low‐Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal‐oriented Clinical Trial Endpoints?

  2017cites this paper
• Statistical evaluation of surrogate outcomes : methodological extensions to ordinal outcomes with applications in acute stroke

  2016cites this paper
• Statistical evaluation of surrogate endpoints with examples from cancer clinical trials

  2016cites this paper
• Estimating Treatment Effects using Multiple Surrogates: The Role of the Surrogate Score and the Surrogate Index

  2016cites this paper
• Statistical approaches for evaluating surrogate outcomes in clinical trials: A systematic review

  2016cites this paper
• Design and Analysis of Clinical Trials for Predictive Medicine

  2015cites this paper
• Statistical Validation of Surrogate Markers in Clinical Trials

  2014cites this paper
• Center-within-trial versus trial-level evaluation of surrogate endpoints

  2014cites this paper
• Statistical Evaluation of Surrogate Endpoints in Clinical Studies

  2014cites this paper
• The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy

  2014cites this paper
• Surrogate endpoints in liver surgery related trials: a systematic review of the literature.

  2013cites this paper
• A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials.

  2012influential citation
• Bioinformatics advances for clinical biomarker development.

  2012cites this paper
• An information-theoretic approach to surrogate-marker evaluation with failure time endpoints

  2011cites this paper
• Potential surrogate endpoints in cancer research – some considerations and examples

  2011cites this paper
• Quest for new genomic and proteomic biomarkers in neurology

  2011cites this paper
• Quest for New Ge Nomic a Nd Proteomic Biomarkers iN Neurolo Gy

  2011cites this paper
• Multivariate and Multistage Survival Data Modeling

  2011cites this paper
• Statistical Criteria for Surrogate Endpoint and Applications : A Review

  2010influential citation
• Biomarkers and surrogate end points—the challenge of statistical validation

  2010cites this paper
• Development of novel genomic blood biomarkers for neurodegenerative diseases.

  2010cites this paper
• Random Effects Models for Longitudinal Data

  2010influential citation
• A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials

  2010influential citation
• Adjustment for the measurement error in evaluating biomarkers

  2010cites this paper
• بررسی اعتبار جانشینی سایتوکاینهای Th1 و Th2 در بیماران مبتلا به عارضه پوستی ناشی از اثرهای درازمدت گاز خردل

  2009cites this paper
• The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)

  2009cites this paper
• Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials

  2009cites this paper
• Chipping away at diagnostics for neurodegenerative diseases.

  2009cites this paper
• Investigating Association Between Behavior, Corticosterone, Heart Rate, and Blood Pressure in Rats Using Surrogate Marker Evaluation Methodology

  2009cites this paper
• Prognostic and surrogate markers for outcome in the treatment of pulmonary tuberculosis

  2009cites this paper
• Study of Surrogacy Validation of Th1, Th2 in Long-Term Skin Effects of Exposure to Mustard Gas

  2009cites this paper
• Cancer drug development with the help of radiopharmaceuticals: academic experience.

  2009cites this paper
• Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective

  2008cites this paper
• The role of clinical imaging in oncological drug development.

  2008cites this paper
• Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective

  2008cites this paper
• The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials

  2008cites this paper
• Flexible modelling techniques and use of historical controls in animal studies

  2008cites this paper
• RNA biomarkers of Parkinson's disease: developing tools for novel therapies.

  2008cites this paper
• Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.

  2008cites this paper
• Επινεφριδιακά ανδρογόνα σε μετεμμηνοπαυσιακές γυναίκες με και χωρίς καρκίνο του μαστού και διερεύνηση της σχέσης τους με την TH1/TH2 ανοσιακή απάντηση

  2007cites this paper
• Hepatology may have problems with putative surrogate outcome measures.

  2007cites this paper
• The opportunities and challenges of developing imaging biomarkers to study lung function and disease.

  2007cites this paper
• Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints

  2007influential citation
• Surrogate Marker Evaluation from an Information Theory Perspective

  2007cites this paper
• 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.

  2006cites this paper
• Imaging response assessment in oncology

  2006cites this paper